Premium
The use of high‐dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome
Author(s) -
Romero R,
Espinoza J,
Gotsch F,
Kusanovic JP,
Friel LA,
Erez O,
MazakiTovi S,
Than NG,
Hassan S,
Tromp G
Publication year - 2006
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2006.01150.x
Subject(s) - metabolomics , proteomics , genomics , biology , computational biology , transcriptome , omics , systems biology , physiology , bioinformatics , genetics , genome , gene , gene expression
High‐dimensional biology (HDB) refers to the simultaneous study of the genetic variants (DNA variation), transcription (messenger RNA [mRNA]), peptides and proteins, and metabolites of an organ, tissue, or an organism in health and disease. The fundamental premise is that the evolutionary complexity of biological systems renders them difficult to comprehensively understand using only a reductionist approach. Such complexity can become tractable with the use of ‘omics’ research. This term refers to the study of entities in aggregate. The current nomenclature of ‘omics’ sciences includes genomics for DNA variants, transcriptomics for mRNA, proteomics for proteins, and metabolomics for intermediate products of metabolism. Another discipline relevant to medicine is pharmacogenomics. The two major advances that have made HDB possible are technological breakthroughs that allow simultaneous examination of thousands of genes, transcripts, and proteins, etc., with high‐throughput techniques and analytical tools to extract information. What is conventionally considered hypothesis‐driven research and discovery‐driven research (through ‘omic’ methodologies) are complementary and synergistic. Here we review data which have been derived from: 1) genomics to examine predisposing factors for preterm birth; 2) transcriptomics to determine changes in mRNA in reproductive tissues associated with preterm labour and preterm prelabour rupture of membranes; 3) proteomics to identify differentially expressed proteins in amniotic fluid of women with preterm labour; and 4) metabolomics to identify the metabolic footprints of women with preterm labour likely to deliver preterm and those who will deliver at term. The complementary nature of discovery science and HDB is emphasised.